- Home
- CRDF vs MIST Comparison
CRDF vs MIST Comparison
Compare CRDF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- MIST
- Stock Information
- Founded
- CRDF 1999
- MIST 2003
- Country
- CRDF United States
- MIST Canada
- Employees
- CRDF N/A
- MIST N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- MIST Health Care
- Exchange
- CRDF Nasdaq
- MIST Nasdaq
- Market Cap
- CRDF 144.4M
- MIST 145.3M
- IPO Year
- CRDF N/A
- MIST N/A
- Fundamental
- Price
- CRDF $2.20
- MIST $2.12
- Analyst Decision
- CRDF Strong Buy
- MIST Strong Buy
- Analyst Count
- CRDF 5
- MIST 3
- Target Price
- CRDF $11.10
- MIST $6.33
- AVG Volume (30 Days)
- CRDF 762.3K
- MIST 1.2M
- Earning Date
- CRDF 11-06-2025
- MIST 11-11-2025
- Dividend Yield
- CRDF N/A
- MIST N/A
- EPS Growth
- CRDF N/A
- MIST N/A
- EPS
- CRDF N/A
- MIST N/A
- Revenue
- CRDF $545,000.00
- MIST N/A
- Revenue This Year
- CRDF N/A
- MIST N/A
- Revenue Next Year
- CRDF N/A
- MIST N/A
- P/E Ratio
- CRDF N/A
- MIST N/A
- Revenue Growth
- CRDF N/A
- MIST N/A
- 52 Week Low
- CRDF $1.90
- MIST $0.63
- 52 Week High
- CRDF $5.64
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CRDF 52.58
- MIST 65.21
- Support Level
- CRDF $1.99
- MIST $1.97
- Resistance Level
- CRDF $2.13
- MIST $2.29
- Average True Range (ATR)
- CRDF 0.10
- MIST 0.09
- MACD
- CRDF 0.04
- MIST 0.01
- Stochastic Oscillator
- CRDF 78.69
- MIST 58.54
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).